# Es Cushing Shared Decision Making Second Line Therapies

> This skill provides a shared decision-making framework for selecting second-line therapies in patients with ACTH-dependent Cushing's syndrome who have persistent hypercortisolism after transsphenoidal surgery or for whom surgery is not feasible. Clinical triggers include "failed TSS", "non-curative pituitary surgery", "persistent UFC elevation post-op", and "surgery contraindicated".

- Skill: `dromlakhani/es-cushing-shared-decision-making-second-line-therapies` (Agent Skill)
- Install (CLI): `npx skillmds@latest add dromlakhani/es-cushing-shared-decision-making-second-line-therapies`
- Raw SKILL.md: https://api.skillmd.com/api/skills/dromlakhani/es-cushing-shared-decision-making-second-line-therapies/raw
- Safety review: pending (external: skill-scanner PASS, skillspector PASS)
- Works with: Claude Code, Claude.ai, OpenAI Codex
- Category: Coding & Dev Tools
- Author: dromlakhani (https://skillmd.com/u/dromlakhani)
- Updated: 2026-09-08
- Page: https://skillmd.com/skills/dromlakhani/es-cushing-shared-decision-making-second-line-therapies

---


# Shared Decision-Making Approach for Second-Line Therapies in ACTH-Dependent Cushing's Syndrome

## STEP 1 — Gather Information
Collect postoperative UFC or late-night salivary cortisol, pituitary MRI to assess residual/visible lesion, comorbidities (diabetes, hypertension, hepatic function, osteoporosis), prior treatments, patient values and preferences, and contraindications to specific therapies (e.g., liver disease for ketoconazole, pregnancy for mifepristone).  
**Action:** Proceed to assess eligibility for each second-line option.

## STEP 2 — Rule In / Rule Out
Determine if a resectable pituitary lesion is visible on postoperative MRI.  
- If lesion visible → consider repeat transsphenoidal surgery (TSS).  
- If no visible lesion → rule out repeat TSS and evaluate medical therapy, radiation, or bilateral adrenalectomy.  
**Decision:** If lesion visible, advance to repeat TSS evaluation; if not, move to medical therapy/radiation/adrenalectomy evaluation.

## STEP 3 — Classify or Stratify
Stratify by clinical urgency and patient factors:  
- Life-threatening hypercortisolism (e.g., severe infection, psychosis) → prioritize bilateral adrenalectomy or rapid-acting medical therapy (etomidate, mifepristone).  
- Non-urgent: classify by patient preference for invasiveness vs medical therapy and comorbidities (e.g., avoid ketoconazole if hepatic impairment; consider mifepristone if diabetes/glucose intolerance).  
**Action:** Assign patient to a preferred modality category: surgical (repeat TSS or adrenalectomy), radiation, or medical therapy.

## STEP 4 — Decide
Based on classification, discuss risks/benefits of specific options within the chosen category with the patient, then initiate shared decision-making to select therapy. Order required pretreatment evaluations (e.g., liver function tests for ketoconazole, pituitary MRI for radiation planning).  
**Action:** Implement chosen second-line therapy and schedule follow-up cortisol assessment at 6–12 weeks.

## Clinical Guardrails / Mimics / Pitfalls
Do not initiate radiation without first confirming medical control of cortisol; avoid bilateral adrenalectomy without discussing lifelong glucocorticoid dependence; do not use ketoconazole in significant hepatic impairment; avoid mifepristone in pregnancy; do not delay treatment in life-threatening hypercortisolism; monitor for Nelson syndrome after adrenalectomy; assess for hypopituitarism after radiation.

## Concrete Clinical Example
A 45‑year‑old woman with persistent UFC 3× normal after TSS shows a 6 mm residual adenoma on MRI, normal liver function, and wishes to avoid lifelong steroids. After discussing options, repeat TSS is selected.

**Source:** Treatment of Cushing’s Syndrome: An Endocrine Society, 2015, DOI:10.1210/jc.2015-1818